Form 4: Vanda Pharmaceuticals CEO Increases Stake with $44,640 Purchase
SEC Form 4 Filing
Vanda Pharmaceuticals' CEO, Mihael Hristos Polymeropoulos, recently acquired 10,000 shares of common stock at an average price of $4.464 per share.
Summary
- Mihael Hristos Polymeropoulos, the President and CEO and Chairman of the Board of Vanda Pharmaceuticals Inc., purchased 10,000 shares of VNDA common stock on February 25, 2025.
- The shares were acquired at a weighted average price of $4.464, with individual transactions ranging from $4.445 to $4.48.
- Following the transaction, Polymeropoulos directly owns 2,331,730 shares of Vanda Pharmaceuticals Inc.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CEO's purchase is a positive sign, but it's a relatively small transaction in the context of the overall market capitalization of the company.
Positives
- The CEO's purchase could be interpreted as a sign of confidence in the company's future prospects.
Industry Context
Insider buying is often seen as a positive signal, suggesting that a company's management believes the stock is undervalued. However, it's important to consider the overall context and not rely solely on insider transactions when making investment decisions.
Stakeholder Impact
- The CEO's stock purchase could have a slightly positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 02/25/2025 | Date of the transaction: CEO purchased 10,000 shares of VNDA common stock. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.